BRIEF-Eli Lilly, AstraZeneca announce continuation of clinical trial for AMARANTH

Fri Apr 8, 2016 12:15pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 8 (Reuters) - Eli Lilly And Co :

* Eli Lilly and Company and AstraZeneca announce continuation of pivotal clinical trial for people with early Alzheimer's disease

* AMARANTH, in development as potential treatment for early alzheimer's disease, to continue to Phase 3 of Phase 2/3 seamless trial

* Says AstraZeneca will receive a milestone payment from Lilly now that AZDd3293 has moved into Phase 3 testing

* Says payment will result in Q2 charge of $100 million (pre-tax) to Lilly's GAAP and non-GAAP research and development expense

* Says Lilly and AstraZeneca have also announced planned initiation of a new Phase 3 trial for AZD3293

* Says DAYBREAK will begin enrolling participants in Q3 of 2016 Source text for Eikon: Further company coverage: